RE:RE:RE:FDA Comment: Like many of the questions that arose, this question of BCG priming the MCNA mechanism sent the panel spinning off into another tangent about the relative merits of BCG. Again, again and again they lost sight that the question was about 2nd line refractory, not a treatment that would usurp BCG as the "gold standard". having an FDA appointed moderator might have helped keep things in line. I am hopeful that the discussions with the FDA will be concise and precise and address the specific and only the specific application for MCNA a that they choose to proceed with. We could all do without the irrelevant one upsmanship and wholesale display of self-importance that defined the Adcomm meeting.